Unraveling the role of HIF2α in melanoma progression and epithelial–mesenchymal transition
Open Access
- 1 July 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-18
Abstract
Melanoma is a highly heterogeneous and aggressive malignancy. Hypoxia within the tumor microenvironment is closely associated with tumor progression. However, the role of hypoxia-inducible factor 2α (HIF2α), a key transcription factor, in melanoma remains poorly understood. In this study, transcriptome analysis compared HIF2α expression between melanoma patient and control samples. Single-cell RNA sequencing categorized cells into high- and low-HIF2α expression groups. Ligand–receptor interactions (CellChat), enrichment analysis (GSEA/GSVA), immune regulatory network, and metabolic pathway analyses were performed. The correlation between HIF2α and genes involved in hypoxia, autophagy, and epithelial–mesenchymal transition (EMT) was explored, alongside its relationship with clinical stage. Experimentally, A375 cells were cultured under normoxic and hypoxic conditions, transfected with ShRNA-NC or ShRNA-HIF2α, and mRNA levels of HIF2α, E-cadherin, N-cadherin, and Vimentin were quantified using real-time PCR. Differential expression analysis showed significant upregulation of HIF2α in melanoma samples. Ligand–receptor interaction analysis emphasized its role in modulating the tumor microenvironment. Enrichment analyses (GSEA/GSVA) revealed HIF2α involvement in key oncogenic pathways. Correlation analysis linked HIF2α to genes related to hypoxia, autophagy, and EMT, and its expression was associated with advanced clinical stages. In vitro, hypoxia increased HIF-2α, N-cadherin, and Vimentin mRNA levels, while decreasing E-cadherin. HIF-2α knockdown reversed these effects, promoting E-cadherin and suppressing N-cadherin and Vimentin under hypoxia. This study underscores the critical role of HIF2α in melanoma progression, suggesting its involvement in regulating the tumor microenvironment and associated metabolic pathways. As a potential biomarker and therapeutic target, HIF2α offers new insights into the clinical management and treatment of melanoma.Keywords
Funding Information
- the Handan Science and Technology Research and Development Program (23422083313)
- The government of Hebei Province funded the training project of clinical medical talents (ZF2023224)
This publication has 56 references indexed in Scilit:
- Hypoxia-associated autophagy flux dysregulation in human cancersCancer Letters, 2024
- The treatment of advanced melanoma: Current approaches and new challengesCritical Reviews in Oncology/Hematology, 2024
- Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanomaCancer Letters, 2024
- Association of NRF2 with HIF-2α-induced cancer stem cell phenotypes in chronic hypoxic conditionRedox Biology, 2023
- Targeted Therapy and Immunotherapy in MelanomaDermatologic Clinics, 2022
- Integrated analysis of multimodal single-cell dataCell, 2021
- Glutathione peroxidase 3 (GPX3) suppresses the growth of melanoma cells through reactive oxygen species (ROS)‐dependent stabilization of hypoxia‐inducible factor 1‐α and 2‐αJournal of Cellular Biochemistry, 2019
- Hypoxia upregulates integrin gene expression in microvascular endothelial cells and promotes their migration and capillary‐like tube formationCell Biology International, 2017
- The Molecular Signatures Database Hallmark Gene Set CollectionCell Systems, 2015
- Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapyTrends in Pharmacological Sciences, 2012